CARVYKTI® (ciltacabtagene autoleucel) is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at least one other treatment has not worked or has stopped working. CARVYKTI® is a medicine made from your own white blood cells, which have been changed (genetically modified) to recognize and attack your multiple myeloma cells.
Patients prescribed CARVYKTI may be eligible for the MyCARVYKTI Patient Support Program sponsored by Johnson & Johnson and Legend Biotech. MyCARVYKTI is designed to support eligible patients and their care partner(s) with travel-related expenses during CARVYKTI treatment at an Activated Treatment Center.
The program may offer support with:
Transportation
Lodging
Meals and Out-of-Pocket Travel Expenses
You may receive this support for leukapheresisLeukapheresis:A type of apheresis specifically for collecting white blood cells., infusion, and bridging therapyBridging therapy:A temporary treatment to control multiple myeloma until treatment with CARVYKTI can begin. if administered at the Activated Treatment Center.* To participate in MyCARVYKTI, you must have been prescribed CARVYKTI and meet distance and income eligibility criteria. Participants must reside in the United States or its territories.
*MyCARVYKTI support is available only when you and your care partner(s) remain at or near the Activated Treatment Center during the above treatment trips. MyCARVYKTI may be an option for you if you do not have health insurance. The program is available to eligible patients regardless of insurance coverage.
How do I enroll in MyCARVYKTI?
To find out if you are eligible, contact the MyCARVYKTI program directly at 800-559-7875, option 1, Monday–Friday, 8:00 AM–8:00 PM ET, as soon as you have been prescribed CARVYKTI.
You can speak with your healthcare team for a referral to the MyCARVYKTI Patient Support Program.